Sastasundar Ventures informs about outcome of board meeting

31 Jan 2024 Evaluate
Sastasundar Ventures has informed regarding the outcome of the Meeting of the Board of Directors of the Company held today, the 31st January, 2024: The Un-audited Financial Results of the Company for the quarter and nine months ended 31st December, 2023: Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, the company informed that the Board of Directors of the Company has approved and taken on record the Unaudited Financial Results (both Standalone and Consolidated) for the quarter and nine months ended 31st December, 2023. The said results have been reviewed by the Audit Committee of the Board, A copy of the Unaudited Financial Results (both Standalone and Consolidated) of the Company for the quarter and nine months ended 31st December, 2023 along with the Limited Review Report of the Statutory Auditor thereon is enclosed ; Parimal Kumar Chattaraj (DIN- 00893963), Independent Director would complete the second term of office on March 31, 2024 thereby completing two terms as an Independent Director. The Board took on record the deep appreciation for the services rendered during his tenure as Independent Director; It informed that in relation to the Composite Scheme of Arrangement (the Scheme) for Demerger and Amalgamation amongst Sastasundar Ventures (‘Demerged Company’ or ‘Amalgamated Company’) and Microsec Resources (‘Resulting Company’) and Sastasundar Healthbuddy (Amalgamating Company) under Sections 230 to 232 and other relevant provisions of the Companies Act, 2013, the rules made there under and the provisions of paragraph 3(b) of Part 1(A) of the SEBI Master Circular dated June 20, 2023, the Amalgamated company (post Amalgamation) is required to maintain pre-public shareholding of minimum 25% including QIB of Amalgamating Company. As a part of the process, the company has filed an application with Securities and Exchange Board of India (SEBI) seeking exemption from the aforesaid provision of SEBI Master Circular dated June 20, 2023, for consideration of Mitsubishi Corporation, Japan and Rohto Pharmaceuticals Company, Japan, the public shareholder of Amalgamating Company as public shareholders of Amalgamated Company. Also informed that SEBI vide letter dated January 30, 2024 has informed the company that the competent authority has not acceded the company’s request. 

The above information is a part of company’s filings submitted to BSE.

Sastasundar Ventures Share Price

307.10 -3.85 (-1.24%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Bajaj Finance 1048.45
Shriram Finance 855.60
Aditya Birla Capital 358.85
Chola Invest & Fin. 1730.55
Tata Capital 325.35
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×